Additional financing to fund Advaxis cervical cancer trials Advaxis.

Additional financing to fund Advaxis’ cervical cancer trials Advaxis, Inc., , a leader in developing the next generation of immunotherapies for cancers and infectious diseases, has entered right into a definitive Convertible Notes Buy Agreement with specific accredited investors, for the buy of the aggregate principal value of around $1.2 million of Convertible Promissory Notes for an aggregate purchase price of approximately $1 LevitraPrix.Net .0 million. The closing of the sale of the Notes, beneath the Agreement, is expected to occur on or around January 6, 2012, at the mercy of customary closing circumstances. Under the conditions specified therein, the Notes are convertible, entirely or in part, into common stock at a conversion price of $0.15.

Many individuals with relapsing-remitting MS tend to be prescribed the medication interferon which improves the immune fights and system viruses, but some still knowledge relapses and may continue steadily to develop new areas of damaged brain cells which are noticeable on magnetic resonance imaging . Dr. Alireza colleagues and Minagar conducted a little trial involving 15 patients with an average age of 44.5 years with relapsing-remitting MS who was simply taking interferon for at least half a year and were experiencing symptoms and developing new brain lesions.